ArticleCureus2026
Intravenous Infusion of Autologous Plasma and Buffy Coat Components Enhances Natural Killer Cell Activity: A Case Report.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immune enhancement is increasingly recognized as an important goal not only for patients with chronic illnesses but also for healthy individuals seeking preventive health. Natural killer (NK) cell activity serves as a sensitive biomarker of immune competence, and subclinical deficits may exist even in asymptomatic, otherwise healthy adults. We report a case of a young, female, asymptomatic adult with no underlying disease, in whom markedly decreased NK cell activity was incidentally detected during routine immune function assessment. She had a history of persistent leukopenia, prompting further laboratory testing despite being apparently healthy. No clinical symptoms were present. The patient received intravenous autologous blood therapy, including plasma and buffy coat components, at regular intervals. Serial laboratory monitoring revealed a dramatic and progressive increase in NK cell activity, from a subclinical baseline to well above the normal reference range. Leukocyte and platelet counts remained stable, and no adverse events or subjective symptoms were observed. This case suggests that intravenous autologous blood therapy may enhance NK cell activity in selected individuals with subclinical immune deficits. However, the clinical significance and potential broader applications, including preventive or anti-aging benefits, remain uncertain and require further investigation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.